Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1
- 27 December 2001
- journal article
- fast track
- Published by Wiley in International Journal of Cancer
- Vol. 97 (3) , 278-282
Abstract
Intrinsic or acquired resistance to chemotherapy is responsible for failure of current treatment regimens in breast cancer patients. The Y‐box protein YB‐1 regulates expression of the P‐glycoprotein gene mdr1, which plays a major role in the development of a multidrug‐resistant tumor phenotype. In human breast cancer, overexpression and nuclear localization of YB‐1 is associated with upregulation of P‐glycoprotein. In our pilot study, we analyzed the clinical relevance of YB‐1 expression in breast cancer (n = 83) after a median follow‐up of 61 months and compared it with tumor‐biologic factors already used for clinical risk‐group discrimination, i.e., HER2, urokinase‐type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI‐1). High YB‐1 expression in tumor tissue and surrounding benign breast epithelial cells was significantly associated with poor patient outcome. In patients who received postoperative chemotherapy, the 5‐year relapse rate was 66% in patients with high YB‐1 expression. In contrast, in patients with low YB‐1 expressions, no relapse has been observed so far. YB‐1 expression thus indicates clinical drug resistance in breast cancer. Moreover, YB‐1 correlates with breast cancer aggressiveness: in patients not treated with postoperative chemotherapy, those with low YB‐1 expression are still free of disease, whereas the 5‐year relapse rate in those with high YB‐1 was 30%. There was no significant correlation between YB‐1 expression and either HER2 expression or uPA and PAI‐1 levels. Risk‐group assessment achieved by YB‐1 differed significantly from that by HER2 or uPA/PAI‐1. In conclusion, YB‐1 demonstrated prognostic and predictive significance in breast cancer by identifying high‐risk patients in both the presence and absence of postoperative chemotherapy, independent of tumor‐biologic factors currently available for clinical decision making.Keywords
Funding Information
- State of Bavaria (KKF, project 8756159)
- Berliner Krebsgesellschaft, Interdisciplinary Research Project: Molecular Biology and Clinic of Breast and Ovarian Cancers
This publication has 26 references indexed in Scilit:
- HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15JNCI: Journal of the National Cancer Institute, 2000
- Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapseBreast Cancer Research and Treatment, 1999
- A Synergistic Interaction of Transcription Factors AP2 and YB-1 Regulates Gelatinase A Enhancer-dependent TranscriptionJournal of Biological Chemistry, 1998
- Anthracycline resistance in breast cancer: Clinical applications of current knowledgeEuropean Journal of Cancer, 1995
- P-Glycoprotein — A Marker of Cancer-Cell BehaviorNew England Journal of Medicine, 1995
- A role for Y‐box proteins in cell proliferationBioEssays, 1995
- Immunohistochemical Detection of Hormone Receptors in Breast Carcinomas (ER-ICA, PgR-ICA): Prognostic Usefulness and Comparison with the Biochemical Radioactive-Ligand-Binding Assay (DCC)Gynecologic Oncology, 1994
- Structural and functional properties of the evolutionarily ancient Y‐box family of nucleic acid binding proteinsBioEssays, 1994
- Acidic and basic fibroblast growth factors in human breast tissueEuropean Journal of Cancer, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993